Modality
siRNA
MOA
KRASG12Di
Target
IL-13
Pathway
Cell Cycle
CMLADPKD
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
~Oct 2021
→ ~Jan 2023
Phase 3
Apr 2023
→ Nov 2031
Phase 3Current
NCT05704077
1,804 pts·ADPKD
2024-11→2031-11·Completed
NCT05763675
480 pts·ADPKD
2023-04→2027-09·Recruiting
2,284 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-151.5y awayPh3 Readout· ADPKD
2031-11-155.6y awayPh3 Readout· ADPKD
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Recruit…
P3
Complet…
Catalysts
Ph3 Readout
2027-09-15 · 1.5y away
ADPKD
Ph3 Readout
2031-11-15 · 5.6y away
ADPKD
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05704077 | Phase 3 | ADPKD | Completed | 1804 | ACR20 |
| NCT05763675 | Phase 3 | ADPKD | Recruiting | 480 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |